The authors report the case of a 67-year-old woman with metastatic renal cell carcinoma (RCC) without prior nephrectomy, who had received long-term exposure (38 months) to the oral multi-targeted tyrosine kinase inhibitor (TKI), sunitinib.
She had a sustained clinical and radiological response to her therapy, but had this therapy discontinued due to the rare development of nephrotic syndrome.
Written by:
Quintyne KI, Neenan T, Casserly L, Gupta R. Are you the author?
Department of Medical Oncology, University Hospital Limerick, Limerick, Ireland; Department of Nephrology, University Hospital Limerick, Limerick, Ireland.
Reference: BMJ Case Rep. 2014 May 28;2014. pii: bcr2013201183.
doi: 10.1136/bcr-2013-201183
PubMed Abstract
PMID: 24872478
UroToday.com Renal Cancer Section
